In the monograph concerning hormonal treatment of prostate cancer special attention is paid to androgen deprivation therapy. Molecular, hormonal and cellular mechanisms of prostate cancer pathogenesis and progression are discussed. Results of animal research and clinical use of luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens and low dose of estrogens for androgen deprivation are described.